- PYRIDYL OR PYRIMIDYL MTOR KINASE INHIBITORS
-
The invention relates to compounds or pharmaceutically acceptable salts thereof of formula (I): (I) wherein R1, R2, R3, R4, R4' and R5 are as defined in the description and claims; and comp
- -
-
Page/Page column 107
(2020/12/30)
-
- Sulfonyl pyridine amide derivatives and preparation method thereof
-
The invention relates to a Sulfonyl pyridine amide derivatives and a preparation method thereof; the preparation method comprises the following steps: adding a compound as shown in a structural formula (II), a compound as shown in a structural formula (III), an oxidant, an additive and a heterogeneous biomass supported copper catalyst into a reaction container, adding a solvent, and carrying out astirring reaction at room temperature; and after the reaction is finished, filtering, extracting, concentrating, separating and purifying to obtain the sulfonyl pyridine amide derivative with the structural formula shown in the formula (I). The synthesis method of the sulfonyl pyridine amide derivatives is scientific and reasonable, and a series of sulfonyl pyridine amide derivatives are synthesized by a green and efficient synthesis method by adopting a heterogeneous biomass copper-loaded catalyst for catalytic reaction.
- -
-
Paragraph 0132-0134
(2021/01/15)
-
- Eosin Y (EY) Photoredox-Catalyzed Sulfonylation of Alkenes: Scope and Mechanism
-
Alkyl- and aryl vinyl sulfones were obtained by eosin Y (EY)-mediated visible-light photooxidation of sulfinate salts and the reaction of the resulting S-centered radicals with alkenes. Optimized reaction conditions, the sulfinate and alkene scope, and X-ray structural analyses of several reaction products are provided. A detailed spectroscopic study explains the reaction mechanism, which proceeds through the EY radical cation as key intermediate oxidizing the sulfinate salts.
- Meyer, Andreas Uwe,Straková, Karolína,Slanina, Tomá?,K?nig, Burkhard
-
supporting information
p. 8694 - 8699
(2016/07/07)
-
- Compounds which Modulate the CB2 Receptor
-
Compounds of formula (I) are disclosed. Compounds according to the invention bind to and are agonists, antagonists or inverse agonists of the CB2 receptor, and are useful for treating inflammation. Those compounds which are agonists are additionally usefu
- -
-
Page/Page column 12
(2008/06/13)
-
- 3-Sulfonyl-1-carba-1-dethiacephems
-
The stability of the 1-carba-1-dethiacephalosporin framework has allowed the synthesis of a range of 3-sulfonyl-1-carba-1-dethiacephems unavailable for a variety of reasons in the cephem arena.The known p-nitrobenzyl 7β-(phenylacetamido)-3-oxy>-1-carba-1-dethia-3-cephem-4-carboxylate served as a precursor to this series of compounds.Displacement of the enol triflate with various sulfinates in acetonitrile or DMF and deprotection of the intermediates led to 7β-amino>-3--1-carba-1-dethia-3-cephem-4-carboxylic acids.The 3-sulfonyl-1-carba-1-dethiacephems display potent activity against both Gram-positive and Gram-negative bacteria.The following MIC's (μg/mL) for the 3-cyclopropyl sulfone are representative: Staphylococcus aureus = 4, Streptococcus pyogenes = 1, Haemophilus influenzae = 0.25, Escherichia coli = 0.03, Enterobacter cloacae = 0.25, Proteus rettgeri = 0.25.The excellent in vitro antibacterial activity of this series indicates the potential of the carbacephalosporin framework for exploring substituents which are unknown or which produce unstable cephems.
- Crowell, Thomas A.,Halliday, Basil D.,McDonald, John H.,Indelicato, Joseph M.,Pasini, Carol E.,Wu, Ernie C. Y.
-
p. 2436 - 2442
(2007/10/02)
-